mosapride SR (DWJ1252) / Daewoong Pharma - LARVOL DELTA

Efficacy and Safety of DWJ1252 Compared With Gasmotin Treatment: Once Met 3 Times Tablets. (PubMed, J Neurogastroenterol Motil) - No abstract available

Clinical • Journal

Efficacy and safety of DWJ1252 compared with Gasmotin® in the treatment of functional dyspepsia: a multicenter, randomized, double-blind, active-controlled study. (PubMed, J Neurogastroenterol Motil) - "Adverse events were similar in the 2 groups, and there were no serious adverse events. In patients with FD, DWJ1252 once daily is as effective as Gasmotin® thrice daily, with a similar safety profile."

Clinical • Journal • Dyspepsia • Gastroenterology • Gastrointestinal Disorder

Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (clinicaltrials.gov) - P3; N=124; Completed; Sponsor: Daewoong Pharmaceutical Co. LTD.; Recruiting ➔ Completed

Clinical • Trial completion

Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2) (clinicaltrials.gov) - P3; N=124; Completed; Sponsor: Daewoong Pharmaceutical Co. LTD.; Recruiting ➔ Completed

Clinical • Trial completion